Know Cancer

forgot password

Phase I Trial of Combination of FOLFIRI and SOM 230 in Advanced Gastrointestinal Malignancies

Phase 1
18 Years
Open (Enrolling)
Gastrointestinal Tumor

Thank you

Trial Information

Phase I Trial of Combination of FOLFIRI and SOM 230 in Advanced Gastrointestinal Malignancies

The goal of this clinical research study is to learn if the study drug SOM 230, also known
as Pasireotide long-acting release (LAR), in addition to standard therapy of FOLFIRI (5FU,
leucovorin, and irrinotecan) can shrink or slow the growth of gastrointestinal malignancies.
The safety of this drug in combination with standard chemotherapy (FOLFIRI) will also be
studied. The participant's physical state, changes in the size of the tumor, and laboratory
findings taken while on-study will help us decide if Pasireotide LAR is safe and effective.

Inclusion Criteria:

- Histologically proven metastatic/unresectable gastrointestinal malignancies (colon,
small bowel, pancreas, gastric and esophageal cancer, etc.) not amenable to curative
surgical therapy, for whom FOLFIRI can be considered a standard treatment

- Have had at least 1 prior treatment for all GI tumors except for small bowel
adenocarcinoma as FOLFIRI can be considered standard first line therapy for that
particular tumor.

- Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST)

- ≥ 4 weeks since any major surgery, completion of radiation, or completion of all
prior systemic anticancer therapy (adequately recovered from the acute toxicities of
any prior therapy)

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Adequate bone marrow function as shown by: absolute neutrophil count (ANC) ≥ 1.5 x
10^9/L, Platelets ≥ 100 x 10^9/L, hemoglobin (Hgb) > 9 g/dL

- Adequate liver function as shown by: serum bilirubin ≤ 2 x upper limit of normal
(ULN), and serum transaminases activity ≤ 3 x ULN

- Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN

- Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5
x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can
only be included after initiation of appropriate lipid lowering medication.

- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
within 14 days of the administration of the first study treatment. Women must not be

- Signed informed consent to participate in the study must be obtained from patients
after they have been fully informed of the nature and potential risks by the
investigator (or his/her designee) with the aid of written information

Exclusion Criteria:

- Prior treatment with irinotecan. Irinotecan with radiation will be allowed if > 4

- Any cytotoxic chemotherapy, radiation, immunotherapy, or any investigational drug
within the preceding 3 weeks of starting the study treatment

- History of liver disease, such as cirrhosis or chronic active hepatitis B and C

- History of, or current alcohol misuse/abuse within the past 12 months

- Known gallbladder or bile duct disease, ( ie infection or cholecystitis) acute or
chronic pancreatitis

- Have undergone major surgery within 4 weeks prior to study enrollment

- Uncontrolled brain or leptomeningeal metastases, including patients who continue to
require glucocorticoids for brain or leptomeningeal metastases. Patients who have
been treated at least 4 weeks prior to enrollment, and have a computed tomography
(CT) scan or magnetic resonance imaging (MRI) of brain within 4 weeks of enrollment,
which shows no evidence of progression of disease in brain, are allowed to enroll.

- Patients with uncontrolled diabetes mellitus defined as hemoglobin A1c (HbA1c) >8%
despite therapy or a fasting plasma glucose > 1.5 ULN. Note: At the principal
investigator's discretion, non-eligible patients can be re-screened after adequate
medical therapy has been instituted.

- Symptomatic cholelithiasis

- Have congestive heart failure: New York Heart Association (NYHA) Class III or IV and
unstable angina

- History of syncope or family history of idiopathic sudden death

- Sustained or clinically significant cardiac arrhythmias including sustained
ventricular tachycardia, ventricular fibrillation, clinically significant
bradycardia, advanced heart block (Mobitz II or higher atrioventricular nodal block
AV)) , patients with prolonged corrected QT interval (QTc) (longer than 470
milliseconds) or a history of acute myocardial infarction within the 6 months
preceding enrollment. (The "QT interval" is the time between the start of the Q wave
and the end of the T wave in the cardiac electrical cycle. The "QTc" is the QT
interval corrected for heart rate.)

- Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac
failure, clinically significant/symptomatic bradycardia, or high-grade AV block

- Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by
diabetes or Parkinson's disease), human immunodeficiency virus (HIV), cirrhosis,
uncontrolled hypothyroidism or cardiac failure

- Patients found to have sustained ventricular tachycardia, ventricular fibrillation,
advanced heart block (Mobitz II or higher AV nodal block) , prolonged QTc (average
longer than 470 milliseconds) in the holter monitor at the screening time. (this only
applies to patients in cohorts of 60 mg of SOM 230 or higher)

- Concomitant medication(s) known to prolong the QT interval (patient must be off the
drug for 2 weeks to be eligible)

- Presence of active or suspected acute or chronic uncontrolled infection or with a
history of immunocompromise, including a positive HIV test result

- Any severe and/or uncontrolled medical conditions or other conditions that could
affect their participation in the study such as: Severely impaired lung function; Any
active (acute or chronic) or uncontrolled infection/ disorders; Nonmalignant
medical illnesses that are uncontrolled or whose control may be jeopardized by the
treatment with the study therapy

- Known or suspected allergy or hypersensitivity to any component of FOLFIRI,
somatostatin analogues or any component of the pasireotide or octreotide long acting
release (LAR) formulations

- No active malignancy except for nonmelanoma skin cancer or in situ cervical cancer or
treated cancer from which the patient has been continuously disease free more than 5

- Women pregnant or breast feeding, or women/men able to conceive and unwilling to
practice an effective method of birth control. WOCBP must have a negative serum
pregnancy test within 14 days prior to administration of pasireotide. Oral,
implantable, or injectable contraceptives may be affected by cytochrome P450
interactions, and are therefore not considered effective for this study

- Unwilling to or unable to comply with the protocol

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose (MTD)

Outcome Description:

To determine the maximum tolerated dose (using a standard 3+3 design), of SOM 230 and FOLFIRI.

Outcome Time Frame:

Average of 6 Months Per Participant

Safety Issue:


Principal Investigator

Richard Kim, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

H. Lee Moffitt Cancer Center and Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

September 2011

Completion Date:

December 2013

Related Keywords:

  • Gastrointestinal Tumor
  • colon
  • rectum
  • small bowel
  • pancreas
  • gastric
  • esophageal
  • metastatic
  • unresectable
  • GI
  • combination therapy
  • dose escalation
  • solid tumor
  • Digestive System Neoplasms
  • Gastrointestinal Neoplasms



H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida  33612